Volume : 09, Issue : 08, August – 2022
Title:
36.FORMULATION AND EVALUATION OF PANTOPRAZOLE SODIUM ENTERIC COATED TABLETS USING DIFFERENT SUPER DISINTEGRANTS
Authors :
Ravi Nema*, Rupesh Kumar Jain, Pushpendra Kumar Khangar, Vivek Jain
Abstract :
The aim of the present study is to formulate and evaluate the pantoprazole sodium enteric coated tablets using different super-disintegrants in different ratio’s and to study the physicochemical properties, drug-excipients compatibility studies and to carry out disintegration, dissolution and stability studies. Pantoprazole is a proton pump inhibitor belongs togroup of benzimidazole. This compound inhibits gastric acid formation and thereby it is very efficientfor the treatment of gastric and duodenum ulcers. An enteric coated pantoprazole sodiumtablets were successfully prepared by directcompression method. Nine formulations ofPantoprazole were developed by preparing coretablets using mannitol as diluent, Aerosil as glidant,Magnesium stearate as lubricant, PVPK30 as binderandkollidone, HPC &Explotab as super disintegrants in 3 different concentrations i.e. 5%7.5%, 10% of which F3 formulation with kollidoneas super disintegrant with concentration of 10% wasselected as best formulation as it has shownmaximum drug release of 100.16% within 45 mins.
Key words: Pantoprazole, Formulation, Evaluation, Enteric coated tablets
Cite This Article:
Please cite this article in press Ravi Nemaet al, Formulation And Evaluation Of Pantoprazole Sodium Enteric Coated Tablets Using Different Super Disintegrants.,I ndo Am. J. P. Sci, 2022; 09(8).
,
Number of Downloads : 10
References:
1. Robinson M. New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001;1:S43
2. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole,and rabeprazole in the treatment of acid-related diseases. J Am Pharma Assoc2000;40:52-62.
3. Rani TN, Kumari CT, Reddy BM, Reddy DR. Comparative in vitro evaluation of different commercially available brands of pantoprazole tablets. Int J Pharm Sci Res 2012;3:1108-11.
4. Avner DL. Clinical experience with pantoprazole in gastroesophageal refluxdisease. Clin Ther2000;22:1169-85.
5. Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole asa treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol 2010;3:11-6.
6. Paul S, Bose A, Konar I, Kara PK, Roy T, Mukherjee P. Comparative in vitro characterization of different commercially available brands of pantoprazole-sodium tablets. World J Pharm Sci 2017;6:778-83.
7. Poole P. Pantoprazole. Am J Health System Pharm 2001;58:9991008.
8. Zyl J, Rensburg C, Vieweg W, Fischer R. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastro-esophageal-reflux disease. Digestion 2004;70:61-9.
9. Sanyal AJ, Reddy KR. Vegetative infection of trans-jugular intrahepatic proto-systemic shunts. Gastroenterology 1998;115:110-5.
10. Simon WA, Keeling Der G. An overview of proton pumps inhibitors. Gastroenterol Nurs2003;26:182-90.
11. Robinson M. New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001;1:S43-
12. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharma Assoc 200026:182-90.
13. Anroop N, Rachna G, Rachna K, Shery J, Mahesh A. Formulation and evaluation of enteric coated tablets of proton pump inhibitor. J Basic Clin Pharm 2010;1:215-21.